Quicksilver Scientific

Free Shipping on Orders over $99 (Excludes )
Quicksilver Scientific Logo
Main Menu
Main Menu
0
0
Subtotal: 0.00

No products in the cart.

No products in the cart.

Continue Shopping
US Flag
UK Flag

Full Spectrum Bliss References

  1. Day J. Botany meets archaeology: people and plants in the past. J Exp Biol. 2013; 64(18): 5805-5816.
  2. Naranjo P, Schultes R, et al. (Eds) Urgent need for the study of medicinal plants. Ethnobotany: Evolution of a Discipline, Dioscorides Press, Portland, OR (1995), pp. 362-368.5.
  3. ElSohly MA, Slade D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci. 2005; 78(5): 539-548. doi: https://doi.org/10.1016/j.lfs.2005.09.011
  4. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanuš Lumír O. Cannabidiol – Recent advances. Chem Biodivers. 2007;4(8):1678-1692. doi: https://doi.org/10.1002/cbdv.200790147
  5. Premoli M, Aria F, Bonini SA, et al. Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment. Life Sci. 2019; 224: 120-127. doi: https://doi.org/10.1016/j.lfs.2019.03.053
  6. Maccarrone M, Bab I, Bíró T, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015; 36(5): 277-296. doi: https://doi.org/10.1016/j.tips.2015.02.008
  7. Russo EB. Beyond Cannabis: Plants and the endocannabinoid system. Trends Pharmacol Sci. 2016; 37(7): 594-605. doi: https://doi.org/10.1016/j.tips.2016.04.005
  8. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346(6284): 561-564. doi: https://doi.org/10.1038/346561a0
  9. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993; 365(6441): 61-65. doi: https://doi.org/10.1038/365061a0
  10. Zoltán Járai, Wagner J, Varga K, et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA. 1999; 96(24): 14136-14141. doi: https://doi.org/10.1073/pnas.96.24.14136
  11. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2009; 147(S1): S163-S171. doi: https://doi.org/10.1038/sj.bjp.0706406
  12. Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2009; 152(7): 1092-1101. doi: https://doi.org/10.1038/sj.bjp.0707460
  13. [1] Glass M, Faull RLM, Dragunow M. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997; 77(2): 299-318. doi: https://doi.org/10.1016/s0306-4522(96)00428-9
  14. [1] Brown SM, Wager-Miller J, Mackie K. Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochimica et Biophysica Acta (BBA) – Gene Structure and Expression. 2002; 1576(3): 255-264. doi: https://doi.org/10.1016/s0167-4781(02)00341-x
  15. [1] Grotenhermen F. Cannabinoids. Curr Drug Target -CNS & Neurological Disorders. 2005; 4(5): 507-530. doi: https://doi.org/10.2174/156800705774322111
  16. [1] Morales P, Hurst DP, Reggio PH. Molecular targets of the phytocannabinoids: A complex picture. Prog Chem Org Nat Prod. 2017; 103: 103-131. doi: https://doi.org/10.1007/978-3-319-45541-9_4
  17. [1] Pretzsch CM, Freyberg J, Voinescu B, et al. Effects of cannabidiol on brain excitation and inhibition systems; a randomized placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacol. 2019; 44(8): 1398-1405. doi: https://doi.org/10.1038/s41386-019-0333-8
  18. [1] Fasinu PS, Phillips S, ElSohly MA, Walker LA. Current status and prospects for cannabidiol preparations as new therapeutic agents. Pharmacotherapy. 2016; 36(7): 781-796. doi: https://doi.org/10.1002/phar.1780
  19. [1] Morales P, Reggio PH, Jagerovic N. An overview on medicinal chemistry of synthetic and natural derivatives of cannabidiol. Front Pharmacol. 2017; 8. doi: https://doi.org/10.3389/fphar.2017.00422
  20. [1] Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005; 30(8): 1037-1043. doi: https://doi.org/10.1007/s11064-005-6978-1
  21. [1] Esposito G, Scuderi C et al. Cannabidiol reduces Ab-induced neuroinflammation and promotes hippocampal neurogenesis through PPARg involvement. PLoS One. 2011; 6: e28668. doi: https://doi.org/10.1371/journal.pone.0028668
  22. [1] Bakas T, van Nieuwenhuijzen PS, Devenish SO, McGregor IS, Arnold JC, Chebib M. The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors. Pharmacol Res. 2017; 119: 358-370. doi: https://doi.org/10.1016/j.phrs.2017.02.022
  23. [1] Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease–successes and failures. FEBS J. 2013; 280(9): 1918-43. doi: https://doi.org/10.1111/febs.12260
  24. [1] McPartland JM, Guy GW, et al. Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS One. 2014; 9(3): e89566
  25. [1] Melamede, R. 2015, February 24. Dr. Robert Melamede, Ph.D. on the endocannabinoid system. Available at: https://www.youtube.com/watch?v=pvaF1r0HL6Y&app=desktop. Accessed April 28, 2019.
  26. [1] Devane W, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992; 258(5090): 1946-1949. doi: https://doi.org/10.1126/science.1470919
  27. [1] Mechoulam R, HanušL. Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids. 2002; 121(1): 35-43. doi: https://doi.org/10.1016/S0009-3084(02)00144-5
  28. [1] Bluett RJ, Joyonna Gamble-George, Hermanson DJ, Hartley ND, Marnett LJ, Patel S. Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. Transl Psychiatry. 2014; 4(7): e408-e408. doi: https://doi.org/10.1038/tp.2014.53
  29. [1] Bishay P, Häussler A, Lim HY, et al. Anandamide deficiency and heightened neuropathic pain in aged mice. Neuropharmacology. 2013; 71: 204-215. doi: https://doi.org/10.1016/j.neuropharm.2013.03.021
  30. [1] Murillo-Rodriguez E, Blanco-Centurion C, Sanchez C, Daniele P, Shiromani PJ. Anandamide Enhances Extracellular Levels of Adenosine and Induces Sleep: An In Vivo Microdialysis Study. Sleep. 2003; 26(8): 943-947. doi: https://doi.org/10.1093/sleep/26.8.943
  31. [1] Witkamp R, Meijerink J. The endocannabinoid system: an emerging key player in inflammation. Curr Opin Clin Nutr Metab Care. 2014; 17(2): 130-8. doi: https://doi.org/10.1097/mco.0000000000000027
  32. [1] Lau BK, Cota D, Cristino L, et al. Endocannabinoid modulation of homeostatic and non-homeostatic feeding circuits. Neuropharmacology. 2017; 124: 38-51. doi: https://doi.org/10.1016/j.neuropharm.2017.05.033
  33. [1] Maroon J, Bost J. Review of the neurological benefits of phytocannabinoids. Surg Neurol Int. 2018; 9(1): 91. doi: https://doi.org/10.4103/sni.sni_45_18
  34. [1] Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants. 2019; 9(1):21. doi: https://doi.org/10.3390/antiox9010021
  35. [1] Juknat A, Pietr M, Kozela E. et al. Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9-tetrahydrocannabinol in BV-2 microglial cells. Br J Pharmacol. 2012; 165(8): 2512-28. doi: https://doi.org/10.1111/j.1476-5381.2011.01461.x
  36. García-Gutiérrez MS, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J. Cannabidiol: A potential new alternative for the treatment of anxiety, depression, and psychotic disorders. Biomolecules. 2020;10(11). doi:https://doi.org/10.3390/biom10111575
  37. Villanueva MRB, Joshaghani N, Villa N, et al. Efficacy, safety, and regulation of cannabidiol on chronic pain: A systematic review. Cureus. 14(7), e26913. doi:https://doi.org/10.7759/cureus.26913
  38. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015; 12(4): 825-836. doi:https://doi.org/10.1007/s13311-015-0387-1
  39. Naftali T, Bar-Lev Schleider L, Almog S, Meiri D, Konikoff FM. Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn’s Disease, a Randomised Controlled Trial. Journal of Crohn’s and Colitis. J Crohns Colitis. 2021; 15(11), 1799-1806. doi:https://doi.org/10.1093/ecco-jcc/jjab069
  40. Irving PM, Iqbal T, Nwokolo C, et al. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis. Inflamm Bowel Dis. 2018; 24(4): 714-724. doi:https://doi.org/10.1093/ibd/izy002
  41. Calapai F, Cardia L, Esposito E, et al. Pharmacological aspects and biological effects of cannabigerol and its synthetic derivatives. Evid Based Complement Alternat Med: eCAM. 2022; 2022: 3336516. doi: https://doi.org/10.1155/2022/3336516
  42. Russo EB, Cuttler C, Cooper ZD, Stueber A, Whiteley VL, Sexton M. Survey of patients employing cannabigerol predominant Cannabis preparations: Perceived medical effects, adverse events, and withdrawal symptoms. Cannabis Cannabinoid Res. 2021; 7(5). doi: https://doi.org/10.1089/can.2021.0058
0
    0
    Your Cart
    You're 99.00 away from free shipping.
    Your cart is empty
    Continue Shopping
      Calculate Shipping
      Apply Coupon